Bredon, M. et al. Faecalibaterium prausnitzii strain EXL01 boosts efficacy of immune checkpoint inhibitors. Oncoimmunology 13, 2374954 (2024).
Jiang, Y. et al. Acetyltransferase from Akkermansia muciniphila blunts colorectal tumourigenesis by reprogramming tumour microenvironment. Gut 72, 1308–1318 (2023).
Kang, X. et al. Roseburia intestinalis generated butyrate boosts anti-PD-1 efficacy in colorectal cancer by activating cytotoxic CD8+ T cells. Gut 72, 2112–2122 (2023).
Siddiqui, I. et al. Intratumoral Tcf1+PD-1+CD8+ T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy. Immunity 50, 195–211 e110 (2019).
Kurtulus, S. et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1−CD8+ tumor-infiltrating T cells. Immunity 50, 181–194 e186 (2019).
Sokol, H. et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA 105, 16731–16736 (2008).
Gao, Y. et al. Faecalibacterium prausnitzii abrogates intestinal toxicity and promotes tumor immunity to increase the efficacy of dual CTLA4 and PD-1 checkpoint blockade. Cancer Res. 83, 3710–3725 (2023).
Effendi, R. et al. Akkermansia muciniphila and Faecalibacterium prausnitzii in immune-related diseases. Microorganisms 10, 2382 (2022).
Chen, B. et al. Gut bacteria alleviate smoking-related NASH by degrading gut nicotine. Nature 610, 562–568 (2022).
Ugbogu, E. A., Schweizer, L. M. & Schweizer, M. Contribution of model organisms to investigating the far-reaching consequences of PRPP metabolism on human health and well-being. Cells 11, 1909 (2022).
Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
Huyghe, J. R. et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nat. Genet. 51, 76–87 (2019).
Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415–1424 (2021).
Tanikawa, C. et al. GWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12. Carcinogenesis 39, 652–660 (2018).
Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
Jiang, S. S. et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31, 781–797.e789 (2023).
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021).
Derosa, L. et al. Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat. Med. 28, 315–324 (2022).
Frankel, A. E. et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19, 848–855 (2017).
Lee, K. A. et al. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma. Nat. Med. 28, 535–544 (2022).
McCulloch, J. A. et al. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1. Nat. Med. 28, 545–556 (2022).
Brandilyn, A. et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. Genome Med 11, 61 (2019).
Bertrand, R. E. et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374, 1632–1640 (2021).
Zheng, Y. et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J. Immunotherapy Cancer 7, 193 (2019).
Yufeng, L. et al. Effects of gut microbiota on immune checkpoint inhibitors in multi-cancer and as microbial biomarkers for predicting therapeutic response. Med 6, 100530 (2025).
Chang, J. W. et al. Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer. Biomed J. 47, 100698 (2024).
Coutzac, C. et al. Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. Nat. Commun. 11, 2168 (2020).
Banushi, B., Joseph, S. R., Lum, B., Lee, J. J. & Simpson, F. Endocytosis in cancer and cancer therapy. Nat. Rev. Cancer 23, 450–473 (2023).
Hu, Z. et al. Glycolysis drives STING signaling to facilitate dendritic cell antitumor function. J. Clin. Invest. 133, e166031 (2023).
Croft, S., Wong, Y. C., Smith, S. A., Flesch, I. E. A. & Tscharke, D. C. Surprisingly effective priming of CD8+ T cells by heat-inactivated vaccinia virus virions. J. Virol. 94, 01486-20 (2020).
Guichard, A., Nizet, V. & Bier, E. RAB11-mediated trafficking in host–pathogen interactions. Nat. Rev. Microbiol. 12, 624–634 (2014).
Ren, Y. et al. TRAPPC4 regulates the intracellular trafficking of PD-L1 and antitumor immunity. Nat. Commun. 12, 5405 (2021).
Ullrich, O., Reinsch, S., Urbe, S., Zerial, M. & Parton, R. G. Rab11 regulates recycling through the pericentriolar recycling endosome. J. Cell Biol. 135, 913–924 (1996).
Lachance, V. et al. Ubiquitylation and activation of a Rab GTPase is promoted by a β2AR-HACE1 complex. J. Cell Sci. 127, 111–123 (2014).
Wu, Y., Chen, W., Xu, Z. P. & Gu, W. PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition. Front. Immunol. 10, 2022 (2019).
Zhu, L. et al. PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1. Front. Immunol. 15, 1486888 (2024).
Doroshow, D. B. et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18, 345–362 (2021).
Cao, H. et al. Liposomes coated with isolated macrophage membrane can target lung metastasis of breast cancer. ACS Nano 10, 7738–7748 (2016).
Donohoe, D. R. et al. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol. Cell 48, 612–626 (2012).
Zhang, M. et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS ONE 9, e109146 (2014).
Trompette, A. et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159–166 (2014).
Cunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M. & Ruggero, D. Protein and nucleotide biosynthesis are coupled by a single rate-limiting enzyme, PRPS2, to drive cancer. Cell 157, 1088–1103 (2014).
He, Y. et al. Soluble PD-L1: a potential dynamic predictive biomarker for immunotherapy in patients with proficient mismatch repair colorectal cancer. J. Transl. Med. 21, 25 (2023).
Zhang, L. et al. The adhesin RadD enhances Fusobacterium nucleatum tumour colonization and colorectal carcinogenesis. Nat. Microbiol. 9, 2292–2307 (2024).
Wong, C. C. & Yu, J. Gut microbiota in colorectal cancer development and therapy. Nat. Rev. Clin. Oncol. 20, 429–452 (2023).
Wang, K. et al. Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target. Science 381, eadd5787 (2023).
Li, B. et al. Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. Cell 188, 3823–3842 e3821 (2025).
Kurilshikov, A. et al. Large-scale association analyses identify host factors influencing human gut microbiome composition. Nat. Genet. 53, 156–165 (2021).
Papadimitriou, N. et al. Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. Nat. Commun. 11, 597 (2020).
Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife 7, e34408 (2018).
Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832 (2013).
Li, X. et al. Therapeutic effect of Faecalibacterium longum CM04-06 on DSS-induced ulcerative colitis in mice. J. Appl. Microbiol. 136, lxaf119 (2025).
Zou, Y. et al. Characterization and description of Faecalibacterium butyricigenerans sp. nov. and F. longum sp. nov., isolated from human faeces. Sci. Rep. 11, 11340 (2021).
Sakamoto, M. et al. Genome-based, phenotypic and chemotaxonomic classification of Faecalibacterium strains: proposal of three novel species Faecalibacterium duncaniae sp. nov., Faecalibacterium hattorii sp. nov. and Faecalibacterium gallinarum sp. nov. Int. J. Syst. Evol. Microbiol. https://doi.org/10.1099/ijsem.0.005379 (2022).
Kovalchuk, S. I., Jensen, O. N. & Rogowska-Wrzesinska, A. FlashPack: fast and simple preparation of ultrahigh-performance capillary columns for LC-MS. Mol. Cell. Proteomics 18, 383–390 (2019).
Perkins, D. N., Pappin, D. J., Creasy, D. M. & Cottrell, J. S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551–3567 (1999).
Sonoda, T. et al. Rat liver phosphoribosylpyrophosphate synthetase is activated by free Mg2+ in a manner that overcomes its inhibition by nucleotides. Biochim. Biophys. Acta 1387, 32–40 (1998).
Ma, J. et al. iProX: an integrated proteome resource. Nucleic Acids Res. 47, D1211–D1217 (2019).
Chen, T. et al. iProX in 2021: connecting proteomics data sharing with big data. Nucleic Acids Res. 50, D1522–D1527 (2022).